Receptors, Tumor Necrosis Factor, Type II
"Receptors, Tumor Necrosis Factor, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor necrosis factor receptor subtype that is expressed primarily in IMMUNE SYSTEM cells. It has specificity for membrane-bound form of TUMOR NECROSIS FACTORS and mediates intracellular-signaling through TNF RECEPTOR ASSOCIATED FACTORS.
|Receptors, Tumor Necrosis Factor, Type II
- Receptors, Tumor Necrosis Factor, Type II
- Receptors, Tumor Necrosis Factor, Member 1B
- TNFR p75
- Tumor Necrosis Factor Receptor 75
- Tumor Necrosis Factor Receptor 2
- Tumor Necrosis Factor Receptor Type 2
- Tumor Necrosis Factor Receptor Type II
- Antigens, CD120b
- CD120b Antigens
- TNFRSF1B Receptor
- Receptor, TNFRSF1B
- Tumor Necrosis Factor Receptor Superfamily, Member 1B
- CD 120b Antigen
- 120b Antigen, CD
- Antigen, CD 120b
- CD120b Antigen
- Antigen, CD120b
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor, Type II".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor, Type II".
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor, Type II" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor, Type II" by people in Profiles.
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. Arthritis Rheumatol. 2021 06; 73(6):1005-1013.
Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):128-135.
Construct validation of the dietary inflammatory index among postmenopausal women. Ann Epidemiol. 2015 Jun; 25(6):398-405.
Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323. Diabetes Care. 2014 May; 37(5):e108-9.
Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 2013 Aug; 36(8):2317-23.
TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells. Eur J Immunol. 2011 Feb; 41(2):335-44.
Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. Am J Obstet Gynecol. 2009 Jun; 200(6):630.e1-8.
Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-induced leukocyte-endothelial interaction in vivo. Blood. 2007 Mar 01; 109(5):1938-44.
New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci. 2004 Dec; 1035:290-315.